



1653
#4
PATENT APPLICATION
Dmt
6-30-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Virginia L. Price and Sharon T. Wong-Madden

RECEIVED

Serial No.: 10/080,428

Group Art Unit No.: 1653

JUN 10 2003

Filed: February 22, 2002

Examiner: Unknown

TECH CENTER 1600/2900

For: COMPOSITIONS AND METHODS FOR
PRODUCTION CELL CULTURE

Docket No.: 3141-A

INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form and provide(s) a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 09-0089 in the name of Immunex Corporation.

Respectfully submitted,


Kathleen Fowler
Attorney for Applicant(s)
Registration No.: 40,611
Phone: (206) 265-4847
Date: June 4, 2003

Please send all future correspondence to:

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
(206) 587-0430

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

June 4, 2003
Date

Kathleen F. Prindle
Kathleen F. Prindle

Modified Form PTO-1449

Atty. Docket No.

3141-A

Serial No.

10/080.428

Applicant

Virginia L. Price and Sharon T. Wong-Madden

Filing Date

February 22, 2002

Group

1653

LIST OF REFERENCES CITED BY APPLICANT

JUN 06 2003

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	6,465,246 B1	10/15/02	Mueller et al.			RECEIVED
	A2						JUN 10 2003
	A3						
	A4						
	A5						
	A6						
	A7						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
	B1	EP 0 922 768 A2	6/16/99	EP			
	B2						
	B3						
	B4						
	B5						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Nielsch et al., "Changes in NF-κB and ISGF3 DNA binding activities are responsible for differences in MHC and β-IFN gene expression in Ad5- versus Ad12-transformed cells," <i>The EMBO Journal</i> 10(13):4169-4175, 1991
C2	Mouzaki et al., "Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor-κB," <i>Eur. J. Immunology</i> 25:2177-2182, 1995
C3	Mori et al., "Production of Interleukin 8 in adult T-cell leukemia cells: possible transactivation of the Interleukin 8 gene by human T-cell leukemia virus Type I tax," <i>Cancer Research</i> 55(16):3592-3597, 1995
C4	Zandi et al., "The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation," <i>Cell</i> 91:243-252, 1997
C5	DiDonato et al., "A cytokine-responsive IκB kinase that activates the transcription factor NF-κB," <i>Nature</i> 388:548-554, 1997
C6	Zandi et al., "Direct phosphorylation of IκB by IKKα and IKKβ: discrimination between free and NF-κB-bound substrate," <i>Science</i> 281:1360-1363, 1998
C7	Mori et al., "Human T-cell leukemia virus Type I tax transactivates human <i>Interleukin 8</i> gene through acting concurrently on AP-1 and Nuclear Factor-κB-like sites," <i>Cancer Research</i> 58:3993-4000, 1998
C8	Levkau et al., "Apoptosis overrides survival signals through a caspase-mediated dominant-negative NF-κB loop," <i>Nature Cell Biology</i> 1(4):227-233, 1999
C9	International Search Report, PCT/US02/05652, mailed January 15, 2003

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.